Dillon Cockrell, GU Medical Oncologist at Duke Cancer Institute, shared Daniel George’s post on LinkedIn, adding:
“Great first day at GU26 with important progress for Prostate Cancer patients, podium talks from Daniel George (data update and PROs from CAPITELLO281 for PTEN deficient mHSPC) and Andrew Armstrong (updates from PCWG4 to frame the future of prostate cancer research), and a peak into the future of AI and oncology research from the keynote.”
Quoting Daniel George, Director of Genitourinary (GU) Oncology at Duke Cancer Institute, Professor of Medicine and Surgery, on LinkedIn:
“Highlights of day 1 (prostate cancer day) at GU ASCO26, including AI impacts on practicing-changing clinical research and refreshed guidelines for clinical research.”
Other articles featuring Dillon Cockrell and Daniel George on OncoDaily.